On June 9, 2021 KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported its expected addition to the broad-market Russell 3000 Index and the Russell 2000 Index in accordance with the 2021 Russell indexes annual reconstitution (Press release, KemPharm, JUN 9, 2021, View Source [SID1234583773]). KemPharm’s anticipated inclusion in the Russell indexes will be effective after the U.S. market opens on Monday, June 28, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The expected addition of KemPharm to the Russell indexes is the latest milestone during what has been a truly transformational year for the Company. In just the last six months, we have received FDA approval for our lead drug candidate AZSTARYS, completed a series of financial transactions that allowed KemPharm to up-list our stock to The Nasdaq Capital Market, extinguished all of our debt, and procured a substantial amount of new capital," stated Travis Mickle, Ph.D., President and CEO of KemPharm. "The Russell indexes are widely used investment benchmarks for index funds and active portfolio strategies. Our inclusion is an important validation and should help our efforts to propel long-term shareholder value, expand awareness of KemPharm within the investment community, increase the liquidity of our stock, and broaden our shareholder base."

The annual reconstitution of the Russell indices is conducted by FTSE Russell, a leading global index provider, and captures the 4,000 largest U.S. equities as of May 7, objectively ranking them by total market capitalization and style attributes. Membership in the U.S. all-cap Russell 3000 Index remains in place for one year and means automatic inclusion in the appropriate growth and value style indexes. Inclusion in the Russell 3000 Index also means automatic inclusion in either the large-cap Russell 1000 Index or the small-cap Russell 2000 Index. Approximately $10.6 trillion in assets are benchmarked against Russell’s U.S. indices.

About FTSE Russell:

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indices that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes that are used by institutional and retail investors globally. FTSE Russell is wholly owned by the London Stock Exchange Group. For more information, visit www.ftserussell.com.

About AZSTARYS:

AZSTARYS is an FDA-approved, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years or older. AZSTARYS consists of SDX, KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate release d-MPH.

The complete approved prescribing information for AZSTARYS may be downloaded in PDF format here: View Source

On June 9, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported the publication of an e-Poster titled ‘A novel drug response predictor (DRP) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib’ at the European Association for Cancer Research (EACR) 2021 Virtual Congress held from 9 – 12 June 2021 (Press release, Allarity Therapeutics, JUN 9, 2021, View Source [SID1234583772]). The e-Poster is also available on the Company’s website on: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The e-Poster describes Allarity’s latest research into the Company’s novel companion diagnostic for dovitinib, known as the Dovitinib-DRP (Drug Response Predictor), and details the identified 58 genes (out of 25,000 expressed genes) that are relevant to the sensitivity or resistance of cancer cell lines to the drug.

Among the identified genes predictive of response/resistance to dovitinib are those associated with FGFR, PDGF, VEGF, PI3K/Akt/mTOR and topoisomerase pathways. About half of the identified 58 genes have no previously published link to known biology of dovitinib action in tumor cells. Accordingly, the findings presented in the e-Poster confirm many of pathways known to be targeted by dovitinib, but also identifies novel mechanisms of drug resistance, such as ABC transporter F1. The results presented in the e-Poster provide a deeper understanding of why the Dovitinib-DRP is predictive of drug response/resistance to dovitinib and has the potential to serve as a companion diagnostic for the drug.

Dovitinib is Allarity’s most advanced clinical asset. The Company plans to file a New Drug Application ("NDA") with the U.S. Food and Drug Administration (FDA) for the approval of dovitinib for the treatment of renal cell carcinoma (RCC, kidney cancer) during 2021 in patients selected with the Dovitinib-DRP. The Company previously submitted, in April 2021, a premarket approval application (PMA) to the U.S. FDA for use of the Dovitinib-DRP as a companion diagnostic to select RCC patients most likely to respond to dovitinib. The Dovitinib-DRP, if approved by the U.S. FDA, will be the first clinically validated, complex gene expression signature used as a companion diagnostic to select patients most likely to respond to a given cancer therapeutic.

Dr. Steen Knudsen, Ph.D., CSO of Allarity Therapeutics commented, "We often find that half of the genes in a DRP constitute known biology while the other half can be considered new, unknown biology reflecting the interaction between a drug and the target cell. That is part of the strength of the DRP platform and we are pleased to share these new findings with the scientific community attending the EACR conference, as we continue to advance our DRP for dovitinib as a companion diagnostic for the drug."

On June 9, 2021 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2021 Life Sciences Conference. Details are as follows (Press release, Syros Pharmaceuticals, JUN 9, 2021, View Source [SID1234583771]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JMP Securities 2021 Life Sciences Conference:
Date: Wednesday, June 16
Time: 1:00 p.m. ET

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

On June 9, 2021 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state of New Jersey’s Technology Business Tax Certificate Transfer Program (Press release, Soligenix, JUN 9, 2021, View Source,000-in-Non-Dilutive-Funding-Through-New-Jersey-Technology-Business-Tax-Certificate-Transfer-Program [SID1234583770]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Receipt of this non-dilutive funding is a welcomed addition to our non-dilutive government grant funding," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "This is our eleventh year receiving Net Operating Loss (NOL) funding. Over this time period, we have received approximately $6.5 million in non-dilutive NOL funding that has allowed us to advance our rare disease pipeline to where we are today. We are, again, very grateful for New Jersey Economic Development Authority’s (NJEDA) continued support of its biotechnology industry."

This competitive program enables approved technology and biotechnology businesses to sell their unused NOL Carryovers and unused Research and Development (R&D) Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey. This allows businesses with NOLs to turn their tax losses and credits into cash proceeds to fund additional R&D, purchase equipment and/or facilities, or cover other allowable expenditures. The NJEDA determines eligibility for the program, the New Jersey Division of Taxation determines the value of the available tax benefits (NOLs and R&D Tax Credits), and the New Jersey Commission on Science and Technology evaluates the technology and its viability. The State of New Jersey was the originator of this program and the first state to implement and fund it.

On June 19, 2021 TG Therapeutics, Inc. (NASDAQ: TGTX), reported the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021 (Press release, TG Therapeutics, JUN 9, 2021, View Source [SID1234583769]). Details of the data presentations are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies

Abstract Book Number: 236
Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST
Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia
Poster Presentation Title: Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma

Abstract Book Number: 241
Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST
Lead Author: Gaël Roué, PhD, Lymphoma Translational Group leader, Josep Carreras Leukaemia Research Institute (IJC)
The above abstracts are now available in the 16th ICML abstract book, published online at View Source Additional information is available via the ICML meeting website at www.lymphcon.ch.

At the time of each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm